| 000 | 01558 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517111859.0 | ||
| 264 | 0 | _c20171212 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1476-5365 | ||
| 024 | 7 |
_a10.1038/bmt.2016.217 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRashidi, A | |
| 245 | 0 | 0 |
_aPost-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cDec 2016 |
||
| 300 |
_a1561-1564 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Donors |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xprevention & control |
| 650 | 0 | 4 | _aHaplotypes |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHistocompatibility |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPremedication |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aSlade, M | |
| 700 | 1 | _aDiPersio, J F | |
| 700 | 1 | _aWestervelt, P | |
| 700 | 1 | _aVij, R | |
| 700 | 1 | _aRomee, R | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 51 _gno. 12 _gp. 1561-1564 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bmt.2016.217 _zAvailable from publisher's website |
| 999 |
_c26329764 _d26329764 |
||